Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Healthtrust
US Army
Harvard Business School
McKesson
Baxter
Express Scripts
QuintilesIMS
Federal Trade Commission
Teva

Generated: October 17, 2017

DrugPatentWatch Database Preview

BOSULIF Drug Profile

« Back to Dashboard

Which patents cover Bosulif, and what generic Bosulif alternatives are available?

Bosulif is a drug marketed by Pf Prism Cv and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has forty-four patent family members in twenty-eight countries and one supplementary protection certificate in one country.

The generic ingredient in BOSULIF is bosutinib monohydrate. There are five drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the bosutinib monohydrate profile page.

Summary for Tradename: BOSULIF

US Patents:5
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Bulk Api Vendors: see list71
Clinical Trials: see list6
Patent Applications: see list2
Drug Prices:see details
DailyMed Link:BOSULIF at DailyMed

Pharmacology for Tradename: BOSULIF

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pf Prism Cv
BOSULIF
bosutinib monohydrate
TABLET;ORAL203341-001Sep 4, 2012RXYesYes► Subscribe► SubscribeYY ► Subscribe
Pf Prism Cv
BOSULIF
bosutinib monohydrate
TABLET;ORAL203341-001Sep 4, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Pf Prism Cv
BOSULIF
bosutinib monohydrate
TABLET;ORAL203341-001Sep 4, 2012RXYesYes► Subscribe► SubscribeY ► Subscribe
Pf Prism Cv
BOSULIF
bosutinib monohydrate
TABLET;ORAL203341-002Sep 4, 2012RXYesNo► Subscribe► SubscribeY ► Subscribe
Pf Prism Cv
BOSULIF
bosutinib monohydrate
TABLET;ORAL203341-002Sep 4, 2012RXYesNo► Subscribe► SubscribeYY ► Subscribe
Pf Prism Cv
BOSULIF
bosutinib monohydrate
TABLET;ORAL203341-002Sep 4, 2012RXYesNo► Subscribe► Subscribe► Subscribe
Pf Prism Cv
BOSULIF
bosutinib monohydrate
TABLET;ORAL203341-001Sep 4, 2012RXYesYes► Subscribe► Subscribe ► Subscribe
Pf Prism Cv
BOSULIF
bosutinib monohydrate
TABLET;ORAL203341-001Sep 4, 2012RXYesYes► Subscribe► SubscribeY ► Subscribe
Pf Prism Cv
BOSULIF
bosutinib monohydrate
TABLET;ORAL203341-001Sep 4, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Pf Prism Cv
BOSULIF
bosutinib monohydrate
TABLET;ORAL203341-001Sep 4, 2012RXYesYes► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for BOSULIF

Drugname Dosage Strength RLD Submissiondate
bosutinibTablets100mg and 500mgBosulif9/6/2016

Non-Orange Book Patents for Tradename: BOSULIF

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,445,496Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-pipera- zinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same► Subscribe
6,297,258 Substituted 3-cyanoquinolines► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: BOSULIF

Country Document Number Estimated Expiration
Canada2543163► Subscribe
Norway20062255► Subscribe
World Intellectual Property Organization (WIPO)2005046693► Subscribe
BrazilPI0613574► Subscribe
Canada2613053► Subscribe
Russian Federation2006113691► Subscribe
Peru01902007► Subscribe
Portugal1902029► Subscribe
SloveniaEP1902029► Subscribe
Israel175424► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: BOSULIF

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0140016 00110Estonia► SubscribePRODUCT NAME: BOSUTINIIB;REG NO/DATE: K(2013)1968 (LOPLIK) 02.04.2013
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Moodys
McKinsey
Accenture
Mallinckrodt
Chubb
Farmers Insurance
Colorcon
Merck
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot